Phase II
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients with Cerebral Amyloid Angiopathy (CAA)
- Study HIC#:2000040004
- Last Updated:03/24/2026
- Age30 years and older
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Yome Tawaldemedhen
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
